RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Beam Therapeutics - Stock

Beam Therapeutics Revenue 2024

Beam Therapeutics Revenue

51.12 M USD

Ticker

BEAM

ISIN

US07373V1052

WKN

A2PY7P

In 2024, Beam Therapeutics's sales reached 51.12 M USD, a -86.47% difference from the 377.71 M USD sales recorded in the previous year.

The Beam Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e596.49-
2028e239.5-
2027e98.97-
2026e49.09-
2025e49.19-
2024e51.12-
2023377.71-
202260.92-
202151.84-
20200.02-
20190.02-
2018--
2017--

Beam Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Beam Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Beam Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Beam Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Beam Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Beam Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Beam Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Beam Therapeutics’s growth potential.

Beam Therapeutics Revenue, Profit, and EBIT History

DateBeam Therapeutics RevenueBeam Therapeutics EBITBeam Therapeutics Net Income
2029e596.49 M undefined0 undefined-121.74 M undefined
2028e239.5 M undefined-373.31 M undefined-323.79 M undefined
2027e98.97 M undefined-476.05 M undefined-412.85 M undefined
2026e49.09 M undefined-509.5 M undefined-386.81 M undefined
2025e49.19 M undefined-463.89 M undefined-399.3 M undefined
2024e51.12 M undefined-464.08 M undefined-398.97 M undefined
2023377.71 M undefined-176.49 M undefined-132.53 M undefined
202260.92 M undefined-338.48 M undefined-289.09 M undefined
202151.84 M undefined-392.47 M undefined-370.64 M undefined
202020,000 undefined-132.76 M undefined-195.87 M undefined
201920,000 undefined-75.15 M undefined-91.04 M undefined
20180 undefined-45.74 M undefined-117.33 M undefined
20170 undefined-7.88 M undefined-9.69 M undefined

Beam Therapeutics stock margins

The Beam Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Beam Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Beam Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Beam Therapeutics's sales revenue. A higher gross margin percentage indicates that the Beam Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Beam Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Beam Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Beam Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Beam Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Beam Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Beam Therapeutics Margin History

Beam Therapeutics Gross marginBeam Therapeutics Profit marginBeam Therapeutics EBIT marginBeam Therapeutics Profit margin
2029e0 %0 %-20.41 %
2028e0 %-155.87 %-135.2 %
2027e0 %-480.98 %-417.13 %
2026e0 %-1,037.89 %-787.97 %
2025e0 %-943.04 %-811.73 %
2024e0 %-907.82 %-780.45 %
20230 %-46.73 %-35.09 %
20220 %-555.61 %-474.54 %
20210 %-757.08 %-714.97 %
20200 %-663,800 %-979,350 %
20190 %-375,750.02 %-455,200 %
20180 %0 %0 %
20170 %0 %0 %

Beam Therapeutics Aktienanalyse

What does Beam Therapeutics do?

Beam Therapeutics Inc. is a leading company in genome editing and was founded in 2018. The company is headquartered in Cambridge, Massachusetts, USA, and aims to develop and bring innovative genome editing technologies to the market. Beam Therapeutics' business model is based on developing groundbreaking technologies that improve and simplify genome editing in living cells. These technologies are used in medicine, agriculture, and other industries to cure diseases, increase crop yields, and improve quality of life. Beam Therapeutics is led by an experienced and competent team composed of leading scientists, engineers, and businesspeople in the industry. The company collaborates closely with industry and academic partners to develop innovative solutions for genome editing. Beam Therapeutics has several business units focused on the development of genome editing technologies and products. One of these business units is the development of CRISPR technologies (Clustered Regularly Interspaced Short Palindromic Repeats), which allow for precise and effective modification of DNA. Beam Therapeutics employs Prime Editors, a new technology that enables the removal, insertion, or replacement of specific DNA sequences. Another important business area for Beam Therapeutics is the development of novel gene therapy products. This involves repairing or removing disease-causing genes in the body to accelerate or even achieve complete recovery. The gene therapy products being developed by Beam Therapeutics have the potential to save lives and provide a long-term solution for certain diseases such as cancer, viral infections, and specific genetic disorders. The company collaborates closely with universities, hospitals, and other institutions to drive the development of gene therapy products. Beam Therapeutics strives to revolutionize the gene therapy industry and improve the treatment of diseases through genome editing. Overall, Beam Therapeutics has an impressive track record and has experienced strong growth in recent years. The company has successfully completed multiple funding rounds to advance its research and development and has hired many talented employees to realize its vision. In summary, Beam Therapeutics is a medical technology company specializing in the development of groundbreaking genome editing technologies and products. The company aims to revolutionize genome editing in medicine, agriculture, and other industries and have a positive impact on people's lives. Beam Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Beam Therapeutics's Sales Figures

The sales figures of Beam Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Beam Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Beam Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Beam Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Beam Therapeutics Stock

How much revenue did Beam Therapeutics generate this year?

Beam Therapeutics has achieved a revenue of 51.12 M USD this year.

How much was the turnover of the company Beam Therapeutics compared to the previous year?

The revenue of Beam Therapeutics has increased by -86.47% decreased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Beam Therapeutics?

The revenue of Beam Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Beam Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Beam Therapeutics so important for investors?

The revenue of Beam Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Beam Therapeutics pay?

Over the past 12 months, Beam Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Beam Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Beam Therapeutics?

The current dividend yield of Beam Therapeutics is .

When does Beam Therapeutics pay dividends?

Beam Therapeutics pays a quarterly dividend. This is distributed in the months of December, March, June, March.

How secure is the dividend of Beam Therapeutics?

Beam Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Beam Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Beam Therapeutics located?

Beam Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Beam Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Beam Therapeutics from 3/3/2014 amounting to 0.225 USD, you needed to have the stock in your portfolio before the ex-date on 2/4/2014.

When did Beam Therapeutics pay the last dividend?

The last dividend was paid out on 3/3/2014.

What was the dividend of Beam Therapeutics in the year 2023?

In the year 2023, Beam Therapeutics distributed 0 USD as dividends.

In which currency does Beam Therapeutics pay out the dividend?

The dividends of Beam Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Beam Therapeutics

Our stock analysis for Beam Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beam Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.